12 essential steps for setting up a pharma cleanroom

Whatever their intended purpose, setting up a cleanroom is set up requires careful consideration both in the design phase, and then in how you use it.

Read more

KCL findings could improve STI vaccines

Researchers have shown how skin vaccination can generate protective CD8 T-cells that are recruited to the genital tissues.

Read more

Array’s ‘extremely compelling’ new colon cancer data spark blockbuster talk

Array Biopharma saw its shares soar on interim data for its three-part therapy in BRAF-positive colon cancer. But analysts say the company still needs to prove that the therapy is safe and that its benefits are durable.

Read more

Lilly to insulin pricing critics: Check out our 50%-off Humalog copy instead

With Congress railing against rising list prices for insulin, Eli Lilly made a commitment to introduce a cheaper generic version of its Humalog in a show of good faith. Consider that a promise kept.

Read more

Merck acquires Peloton Therapeutics for $1 billion

The acquisition of Peloton, which was seeking to go public last week, brings its lead kidney cancer drug candidate to Merck, strengthening its renal cell carcinoma presence

Read more

WuXi to build dedicated vaccine facility, but who’s the client?

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a contract that should produce $150 million a year for 20 years. It just didn’t say who the client is.

Read more

Supreme Court puts Merck’s FDA preemption argument up for another review

Merck’s Fosamax fight has lasted for years—and thanks to the U.S. Supreme Court, Merck now gets another chance to press its case. But the case also centers on a question the entire pharma industry would like resolved: Whether FDA labeling decisions shield drugmakers from liability in state court.

Read more

Hurting for revenue, Mylan shells out $130M for basket of Aspen drugs

With share prices tumbling and a massive drug-price fixing lawsuit hanging over its head, Mylan’s future is looking increasingly spooky. Could a modest acquisition help turn the tide?

Read more